RT Journal Article
SR Electronic
T1 Prevalence and early-life determinants of mid-life multimorbidity: evidence from the 1970 British birth cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.09.20126235
DO 10.1101/2020.06.09.20126235
A1 Gondek, Dawid
A1 Bann, David
A1 Brown, Matt
A1 Hamer, Mark
A1 Sullivan, Alice
A1 Ploubidis, George B.
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.09.20126235.abstract
AB Objectives We sought to: (1) estimate the prevalence of multimorbidity at age 46-48 in the 1970 British Cohort Study—a nationally representative sample in mid-life; and (2) examine the association between early-life characteristics and mid-life multimorbidity in the 1970 British Cohort Study.Design Prospective longitudinal birth cohort.Setting A community based sample from the 1970 British Cohort Study (BCS70).Participants All surviving children born in mainland Britain in a single week in April 1970; the analytical sample was those with valid data at age 46-48 (n=7,951; 2016-2018).Main outcome measure Multimorbidity was operationalised as a binary indicator of two or more long-term health conditions where at least one of these conditions was of physical health. It also included symptom complexes (e.g. chronic pain), sensory impairments, and alcohol problems.Results Prevalence of mid-life multimorbidity was 33.8% at age 46-48. Those with fathers from unskilled social occupational class (vs. professional) at birth had 43% higher risk of mid-life multimorbidity (risk ratio=1.43, 95% confidence interval 1.15 to 1.70). After accounting for a range of potential child and family confounders, an additional kilogram of birthweight was associated with 10% reduced risk of multimorbidity (risk ratio=0.90, 95% confidence interval 0.84 to 0.96); a decrease of one body mass index point at age 10 was associated with 3% lower risk (risk ratio=1.03, 95% confidence interval 1.01 to 1.05); one standard deviation higher cognitive ability score at age 10 corresponded to 4% lower risk (risk ratio=0.96, 95% confidence interval 0.91 to 1.00); an increase of one internalising problem at age 16 was equated with 4% higher risk (risk ratio=1.04, 95% confidence interval 1.00 to 1.08) and of one externalising problem at age 16 with 6% higher risk (risk ratio=1.06, 1.03 to 1.09).Conclusion Prevalence of multimorbidity was high in mid-life (33.8% at age 46-48) in Britain, with those in a more disadvantaged social class a birth being disproportionally affected. Potentially modifiable early-life exposures including early-life social circumstances, cognitive, physical and emotional development were associated with mid-life multimorbidity.What is already known on this topic?Due to differences in outcome definition, estimates of multimorbidity prevalence in mid-life (age 40-60) have varied extensively in high-income countries—from 15 to 80% between 1961 and 2013.There is a lack of contemporary national data in Great Britain describing the burden and nature of multimorbidity according to an agreed definition.The association between early-life risk factors and individual health conditions have been widely studied, however it is unknown if they are associated with multimorbidity.What this study addsPrevalence of multimorbidity in mid-life (age 46-48) was 33.8% in a nationally representative birth cohort in 2016-2018.Disadvantaged early-life parental social class, lower birthweight, lower cognitive ability, higher childhood body-mass index, and a higher number of internalising and externalising problems were found to be associated with a higher mid-life multimorbidity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDawid Gondek is supported by Economic and Social Research Council (ESRC) +3 PhD studentship. The study is also supported by ESRC grant: ES/M001660/1. The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BCS70 has been granted ethical approval for each sweep from 2000 by the National Health Service (NHS) Research Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBCS70 data used in this study have been managed by the Centre for Longitudinal Study and are accessible via the UK data archive. The statistical code for derived variables is available from the correspondence author.